A review looks at one protein as a possible target in glioblastoma
Original title: Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is an expert summary of where research is heading, not a new result.
The short version
Experts looked at a protein called EZH2 to see if it could one day be a target for glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary treatment.
What was studied. This is a review, not a new study. The authors gathered what is already known about a protein called EZH2 in normal cells and in glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary, a type of brain tumor.
What they found. EZH2 helps turn genes off inside cells, and this can help the tumor grow. Having more of it did not always match how long people with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary lived. Still, the authors think it may be worth targeting, because it may help tumors resist treatment.
What this means, and what it doesn't
What it could mean: Scientists see EZH2 as a possible target for future glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary drugs. Drugs that block it might one day help some patients, maybe when used with other drugs. Doctors may need tests to find out which patients could be helped.
What it doesn't mean: This review does not report a new treatment or a new test in patients. The authors say drugs that block EZH2 still face big problems. One problem is getting the drug past the wall that protects the brain. This is not something patients can get today, and it is not a cure.
Source: PubMed, August 29, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.